All In Biotech

Drug Trial Radar · NCT05721729

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Jun 23, 2023

Primary completion

May 1, 2024

Study completion Jun 1, 2025

Sponsor

Lead sponsor
Vogenx, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Conditions

  • Postbariatric Hypoglycemia

Interventions

  • MizagliflozinDrug

    Encapsulated

  • PlaceboDrug

    Encapsulated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glucose NadirTime frame: 0-3 hours following MMTT

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford

    Palo Alto, California

  • University of Colorado / Anschutz Medical Campus

    Aurora, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.